Canon Inc. · Fiscal year ended December 2025

Printing is 54% of Canon's sales.

Canon still naturally brings cameras to mind, and that image is not obsolete: Imaging exceeded ¥1 trillion of sales in 2025 and camera sales grew strongly. But across the whole company, Printing is much larger. It generated ¥2.494 trillion, 54% of sales. Medical and Industrial add another roughly ¥942 billion. Canon did not abandon cameras to become something else; it extended optics, imaging, materials and production technologies into a much broader portfolio.

¥2.494tn2025 Printing net sales
54%Printing share of total net sales
¥1.055tn2025 Imaging net sales

This is not investment advice or a stock recommendation. We reorder company-published primary-source facts to make the shape of the business easier to see.

Canon still naturally brings cameras to mind.

That image is not obsolete.

Imaging exceeded ¥1 trillion of sales in 2025, and the camera business posted double-digit growth.

But across the whole company, another business is much larger.

Net sales are ¥4.625 trillion

More than half of those sales come from something other than cameras.

Printing is ¥2.494tn

Printing itself is not one product category.

The ¥2.49tn spans office, prosumer and production printing

How large is Imaging, which includes the cameras most closely associated with the brand?

Imaging is ¥1.055tn

Printing is roughly 2.4 times the size of Imaging by sales.

DATA VIEW

Printing is more than twice the size of Imaging

2025 business-unit net sales. Shares are company disclosed.

Printing is more than twice the size of Imaging
Printing¥2.49tn / 54%
Imaging¥1.05tn / 23%

The current Canon also extends well beyond those two businesses.

Medical is ¥580.6bn

Another business is less visible to consumers.

Industrial is ¥361.1bn

DATA VIEW

Canon now operates around four business groups

2025 net sales and company-disclosed shares. Shares do not total 100% because business-unit sales include intersegment transactions.

¥2.49tn / 54%Printing
¥580.6bn / 13%Medical
¥1.05tn / 23%Imaging
¥361.1bn / 8%Industrial

Those four pillars did not exist at the beginning.

Canon started as a camera maker in 1937

So the useful story is not that Canon stopped being a camera company.

It is that a camera company kept adding new fields.

That expansion is not only a history of acquisitions.

Printer materials technology is moving into solar cells

A different combination of technologies is moving into regenerative medicine.

Optics and image processing are moving into iPS-cell production

Canon describes this cross-business reuse as part of its development system.

Technologies are not kept inside one business

Cameras have not disappeared from Canon.

In fact, Imaging grew strongly in 2025.

But cameras alone now explain less than a quarter of the company’s sales scale.

THE VIEW AFTER THE NUMBERS

What the numbers suggest

Canon generated ¥4.625 trillion of net sales in 2025.

Its largest business, Printing, generated ¥2.494 trillion, or 54%. Imaging, including cameras, generated ¥1.055 trillion, or 23%. Medical contributed ¥580.6 billion and Industrial ¥361.1 billion.

Cameras remain substantial and Imaging moved above ¥1 trillion in 2025. So there is no need to say Canon is “no longer a camera company.”

Canon started as a camera maker in 1937, then extended its technologies into office equipment, medical systems and industrial equipment.

And the technologies continue to move: printer photoreceptor materials know-how is being applied to solar-cell materials, while optics and image processing are being applied to iPS-cell production.

Canon did not replace one identity with another. It became broader by reusing technologies developed around imaging and precision manufacturing in new markets.

Primary sources used

Canon Annual Report 2025

Canon Inc. · 2026-03-25

Pages used: p.1 / p.12 / p.17 / p.19 / p.21 / p.22 / p.22-23 / p.23

Open source →

NEXT COMPANY

Olympus Corporation · Fiscal year ended March 2026

Look at the next company

From microscopes to gastrocameras: Olympus at ¥1 trillion.

Olympus generated ¥1.0107tn of revenue and ¥97.1bn of operating profit in FY2025. Gastrointestinal Solutions generated ¥697.4bn, or 69%, while Surgical & Interventional Solutions generated ¥313.1bn, or 31%. Japan represented only 10% of sales, leaving roughly 90% outside Japan by site calculation. Olympus began in 1919 with domestic microscope production and developed the world's first practical gastrocamera in 1950. Its Imaging business was transferred in 2021, while Scientific Solutions was separated into Evident and subsequently sold. Today's Olympus is not a diversified optical conglomerate preserving every branch of its past. It is a medtech company that concentrated the long lineage of its technologies for seeing around endoscopy, intervention and treatment.

See the company through the numbers →
¥1.011tnFY2025 consolidated revenue